Speakers - Sachs Associates

More documents

Recommendations

Info

ADDRESS Am Klopferspitz 19 82152 Martinsried/Munich TELEPHONE +49 30 90 50 68-0 FAX +49 30 90 60 68-68 EMAIL info@suppremol.com YEAR FOUNDED 2002 Suppremol www.suppremol.com COMPANY PROFILE Delivering novel therapeutics for the treatment of autoimmune diseases SuppreMol, a privately held biopharmaceutical Company, is developing novel proteins to treat autoimmune diseases. SuppreMol has developed a novel therapeutic concept for the treatment of autoimmune diseases that relies on naturally produced Fc gamma receptors (FcgRs). The Company was founded in 2002 as a spin-off from the Max Planck Institute of Biochemistry. The Company is developing SM101 for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) in Phase II clinical trials. SM101 is designed to be a specific, early onset, long lasting and well tolerated treatment for autoimmune diseases such as ITP, SLE, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS). Further building its platform of selective immunoregulators, SuppreMol is working on antibody programs targeting Fc receptors and other immunomodulatory molecules for alternative treatment strategies in autoimmune conditions. MANAGEMENT Prof Dr Peter Buckel, CEO Dr Robert Phelps, Head of BD and Licensing Dr Peter Sondermann, CSO Sascha Tillmanns, Medical Director t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACT Dr Johanna Holldack, MD Chief Executive Officer ADDRESS TELORMEDIX SA Via della Posta 10 CH-6934 Bioggio Switzerland TELEPHONE +41 (0)91 610 7000 FAX +41 (0)91 610 7031 EMAIL Telormedix@telormedix.com YEAR FOUNDED 2007 Telormedix www.telomedix.com COMPANY PROFILE Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating autoimmune diseases and cancer. Telormedix is particularly interested in the role of Toll-like Receptor 7 (TLR7) for the topical treatment of cancer. The Company’s lead product, TMX-101, is currently in a Phase I/II clinical trial for the treatment of Non- Muscle Invasive Bladder Cancer (NMIBC) and has showed a good safety profile in humans. TMX-101 is a new formulation of a clinically-active small molecule compound with a known and favourable safety profile and a specific immunotherapeutic target. Telormedix has optimized TMX-101 specifically for the localised treatment of bladder cancer, the fifth most prevalent cancer and a disease of significant unmet medical need. TMX-101 will be the first targeted therapy dedicated to bladder cancer and the first to modulate the innate immune system for this indication. The second product, TMX-202, is a small molecule for the topical treatment of skin and bladder cancers that has already provided significant preclinical results. Within the TMX-20X series, the Company also has another product called TMX-201, which is being developed for use as a vaccine adjuvant. Proof of concept has recently been established in relevant animal models. An additional product, TMX-302, is part of a pipeline programme targeting autoimmune diseases. MANAGEMENT Johanna Holldack, MD, CEO Roberto Maj, PharmD, Founder/Head of Drug Development Alcide Barberis, PhD, Head of Research and Collaborations Filippo Riva, MBA, CFO Raffaella Pozzi, PharmD, Head of Clinical Operations Nadia Passini, PhD, Project Management Director t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2:
B I O T E C H I N E U R O P E I N V
Page 3 and 4:
Events Diary For regular updates, s
Page 5 and 6:
Speakers Alexey Eliseev, Managing D
Page 7 and 8:
Speakers Blake M. Paterson, Co-Foun
Page 9 and 10:
Speakers David Slack, Head of Corpo
Page 11 and 12:
Speakers Frank Grams, VP, Head Alli
Page 13 and 14:
Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16:
Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18:
Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20:
Speakers Paul Higham, Managing Dire
Page 21 and 22:
Speakers Richard Goodfellow, CEO, S
Page 23 and 24:
Speakers Søren Moller, Managing In
Page 25 and 26:
CONTACT Robert F Burns, PhD Chief E
Page 27 and 28:
CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30:
CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32:
CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34:
CONTACT Carina Schmidt Chief Execut
Page 35 and 36:
CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38:
CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40:
CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42:
CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90: CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92: CONTACTS Dr Hans Fliri Chairman Sim
Page 93: CONTACTS Dr Raúl Insa Chief Execut
Page 97 and 98: CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100: CONTACTS Piers Morgan Chief Financi
Page 101 and 102: CONTACT Jakob Knudsen Chief Executi
Page 103 and 104: CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106: Supporting Organisations Citigate D
Page 107 and 108: Supporting Organisations Life Scien
Page 109 and 110: Supporting Organisations Swiss Biot
Page 111 and 112: Supporting Organisations Torreya Pa
Page 113: B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?